Edgar Engleman

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

In vivo manipulation of dendritic cells to induce therapeutic immunity.

Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation.

Langerhans cells renew in the skin throughout life under steady-state conditions.

Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases.

Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients.

Dendritic cell-based cancer immunotherapy.

Two isoforms of otubain 1 regulate T cell anergy via GRAIL.

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease.

Using signaling pathways to overcome immune tolerance to tumors.

Developmental origin of interferon-alpha-producing dendritic cells from hematopoietic precursors.

In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity.

Flk2+ myeloid progenitors are the main source of Langerhans cells.

Breaking tolerance to tumors with dendritic cell-based immunotherapy.

Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.

[A possibility of overcoming local tumor immune tolerance by radiofrequency ablation in combination with intratumoral injection of naïve dendritic cell].

Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity.

Natural killer cells trigger differentiation of monocytes into dendritic cells.

CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells.

Breaking self-tolerance to tumor-associated antigens by in vivo manipulation of dendritic cells.

Qa-1(b)-dependent modulation of dendritic cell and NK cell cross-talk in vivo.

Tolerance and chimerism after renal and hematopoietic-cell transplantation.

Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo.

T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size.

In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines.

Chemoselective ligation in the functionalization of polysaccharide-based particles.

Normalization of obesity-associated insulin resistance through immunotherapy.

Obesity predisposes to Th17 bias.

Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.

Regulation of human Th9 differentiation by type I interferons and IL-21.

Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis.

Plasmacytoid dendritic cell dichotomy: identification of IFN-α producing cells as a phenotypically and functionally distinct subset.

The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP.

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.

T(H)1, T(H)2, and T(H)17 cells instruct monocytes to differentiate into specialized dendritic cell subsets.

Induced immune tolerance for kidney transplantation.